Trial purpose
Cancer treatment
Tumor type
Skin
Age
18 - 75
Clinical summary
Summary
People in Australia with brain metastases from melanoma are currently offered whole brain radiotherapy (WBRT) after brain surgery depending on which hospital they attend. This trial seeks to determine if WBRT reduces the spread of melanoma in the brain, and lengthens the time to melanoma returning. This trial will also examine the effect of WBRT on quality of life and brain functions such as memory, speech and concentration. Participants will be randomised to either whole brain radiotherapy or observation following their surgery. 200 people will be recruited from melanoma centres in Australia, New Zealand and other international sites.
Conditions
This trial is treating people with Melanoma
Eligibility
Inclusion
1. 1-3 intracranial metastases on MRI from melanoma, locally treated with either surgical excision and/or stereotactic irradiation. 2. Life expectancy of at least 6 months 3. Aged 18 years or older 4. WBRT must be within 8 weeks of completion of localised treatment and within 4 weeks of randomisation 5. Able to have an MRI brain scan with contrast. ‘estimated Glomerular Filtrate Rate’ (eGFR) is adequate at the discretion of the radiologist and capable of having gadolinium-containing contrast medium for MRI as per practice guidelines 6. Complete localised treatment of all these metastases no more than 6 weeks prior to randomisation 7. An Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less at randomisation 8. CT scan of chest, abdomen and pelvis as a minimum prior to randomisation. Scans must be within 12 weeks of randomisation 9. Serum Lactate Dehydrogenase (LDH) must be = or < 2 x upper limit of normal 10. Able to provide written informed consent
Exclusion
1. Any untreated intracranial disease
2. Any previous intracranial treatment (surgical excision and/or stereotactic irradiation treatment and/or WBRT) prior to this diagnosis of intracranial melanoma
3. Evidence of leptomeningeal disease on pre-local treatment MRI scan
4. Patients with prior cancers, except:
o Those diagnosed more than five years ago with no evidence of disease recurrence within this time;
o Successfully treated basal cell and squamous cell skin carcinoma;
o Carcinoma in-situ of the cervix
5. A medical or psychiatric condition that compromises ability to give informed consent or complete the protocol
6. Positive urine pregnancy test for women of childbearing potential within a week of registration onto the trial
Inclusion
- Your cancer has spread to other parts of the body (metastatic) or has grown into nearby parts of the body (locally advanced).
Exclusion
- You have been diagnosed with a prior or secondary type of cancer.
- You have certain types of non-cancer medical conditions.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ANZCTR *. View further details about this trial on the registry via the links below:
Trial sponsor
Australia and New Zealand Melanoma Trials Group (ANZMTG)
Scientific Title
Whole brain radiotherapy following local treatment of intracranial metastases of melanoma. A randomised phase III trial (Other IDs: ANZMTG 1-07).
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Peer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information